DNDN Related Rumors
-
Dendreon (DNDN) Pops on Takeover Rumors, Short Covering
-
Takeover Target Dendreon (DNDN) Rips Higher
-
Dendreon (DNDN) Pops Intra-Day
-
Dendreon (DNDN) Sees Upside Action
-
Medivation (MDVN) Makes The Best Takeover Target, Not Dendreon (DNDN) - Jefferies
-
Dendreon (DNDN) Gets Takeover Buzz and a New Bull
-
Dendreon (DNDN) Unconfirmed Rumor: SEC Opens Probe on Co.'s Disclosures
-
Dendreon (DNDN) Pops On Renewed Takeover Talk
-
Human Genome (HGSI) Trades Well Above GSK Offer, Other Biotechs See Action
-
Dendreon (DNDN) Sees Action on Renewed Takeover Speculation
-
Dendreon (DNDN) Now a Double on the Year Amid M&A Speculation
-
Baird Raises Its Price Target On Dendreon (DNDN) After New CEO, But Says Don't Count On a Takeout
-
Brean Murray Sees Medivation (MDVN) As a Takeout Target After Strong Data, Sees "Beginning of the End" for Dendreon's (DNDN) Provenge
-
Deutsche Bank Says Dendreon (DNDN) CEO Departure a "Surprise," But New CEO Brings M&A History
-
Dendreon (DNDN) Higher On Amgen (AMGN) Takeover Rumor
-
Bristol-Myers's (BMY) Inhibitex (INHX) Takeover Puts Hep-C, Other Biotechs on M&A Watch
-
Owning Biotech Launch Stocks Is One Strategy To Capture Upside - Goldman Sachs
-
Biotech M&A Will Be In Focus in 2012 - Goldman
-
Biotech Stocks Could See Action On Valeant (VRX) Bid for Cephalon (CEPH): (BIIB) (JAZZ) (DNDN) (REGN) (more...)
-
This Hedge Fund Guru Profited Big-Time From the Buyout of Genoptix (GXDX), See What Other Targets He Is Buying
-
Wall Street Hubbub 9/8: Netezza (NZ) Jumps On Takeover Chatter, ArcSight (ARST) Falls As Sale Hits Snag, New York Times (NYT) Re-Enters the Rumor Mill
-
Dendreon (DNDN) Sees Upside On Chatter
-
Wall Street Hubbub 7/15: JPMorgan's Earnings Quality "Weak", BP On Verge of Asset Sale, AIG's Benmosche Makes More Waves, iPhone 4 Fiasco
-
Leerink Swann Says M&A Is One Reason To Get Involved In Biophama (AGN, DNDN, BMRN, HGSI, more...)
-
Dendreon (DNDN) 17% 4-Day Jump Raises Eyebrows; Is a Deal in the Works?
-
Dendreon (DNDN) Sinks As CMS Weighs Provenge Coverage
-
Dendreon (DNDN) Sees Pressure In After-Hours Action
-
Dendreon (DNDN) Sees Brief Action On Renewed Takeover Speculation
-
Two Stocks With Pending FDA Approval See Interest after Dendreon News (POZN, ITMN)
-
'Takeover Fever' Continues In Biotech After Facet (FACT) Deal, Who's Next?
-
Dendreon (DNDN) Continues Volitle Action On Continued Concerns About a Possible Advisory Panel on Provenge
-
Dendreon (DNDN) Provenge "will not" go before a FDA advisory panel - CNBC
-
Dendreon (DNDN) Flips Green After Falling 9% Earlier
-
Dendreon (DNDN) No Indication Of FDA Panel Review For Provenge - Dow Jones News
-
Dendreon (DNDN) Falls On Rumors of Unexpected FDA Panel On Provenge
-
Biotech Rumor Mill Hopping After Hostile Bid for OSI Pharmaceuticals (OSIP)
-
New Dendreon (DNDN) Board Member Disclosures Revs Up Rumor Mill
-
Biotech Takeover Buzz Continues (VVUS, DNDN, HGSI, IMMU, CEPH)
-
PDL BioPharma (PDLI) Thrown Into Biotech Rumor Mill Today
-
Dendreon (DNDN) Higher On Renewed Takeover Talk
-
Reports Dendreon (DNDN) Has Hired A Financial Advisor
-
Needham Comments on "Who's Next" In Biotech After Bristol-Myers (BMY) Buys Medarex (MEDX)
-
Dendreon (DNDN) and OncoGenex (OGXI) Could See Interest On JNJ's Cougar Biotech Deal
-
Dendreon (DNDN) Sees Strength On Takeover Talk
-
FDA Could Request Additional Confirmatory Trial For Dendreon's (DNDN) Provenge
-
Dendreon (DNDN) Spikes On Presentation News
-
Dendreon (DNDN) Spikes Higher
-
UPDATE: Dendreon (DNDN) Surges On Request For Congressional Hearing on FDA Provenge Review
-
Market Rumors 05/24
-
Rumors of a Securities Class Action Lawsuit on Dendreon (DNDN)
Back to DNDN Stock Lookup
